-
Something wrong with this record ?
Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers
L. Záveský, E. Jandáková, V. Weinberger, L. Minář, V. Hanzíková, D. Dušková, A. Faridová, R. Turyna, O. Slanař, A. Hořínek, M. Kohoutová
Language English Country Netherlands
Document type Journal Article
Grant support
Progres Q28/LF1
Charles University, Prague
Progres Q25/LF1
Charles University, Prague
RVO-VFN 64165
Ministry of Health of the Czech Republic
CZ-DRO FNBr 65269705
Ministry of Health of the Czech Republic
SSD2018\100022
Avast Foundation
1410002385
ČEPS, a.s.
1410002088
ČEPS, a.s.
1410002640
ČEPS, a.s.
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Biomarkers MeSH
- Humans MeSH
- MicroRNAs * metabolism MeSH
- Biomarkers, Tumor genetics MeSH
- Breast Neoplasms * diagnosis genetics pathology MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Gene Expression Regulation, Neoplastic genetics MeSH
- RNA, Small Nuclear MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). METHODS AND RESULTS: In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. CONCLUSIONS: Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019313
- 003
- CZ-PrNML
- 005
- 20220804135543.0
- 007
- ta
- 008
- 220720s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11033-021-07010-8 $2 doi
- 035 __
- $a (PubMed)34993725
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Záveský, Luděk $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic. ludek.zavesky@gmail.com $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic. ludek.zavesky@gmail.com $1 https://orcid.org/0000000195927535 $7 jo2013742232
- 245 10
- $a Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers / $c L. Záveský, E. Jandáková, V. Weinberger, L. Minář, V. Hanzíková, D. Dušková, A. Faridová, R. Turyna, O. Slanař, A. Hořínek, M. Kohoutová
- 520 9_
- $a BACKGROUND: Breast cancer is a leading cause of cancer-related death in women. Most cases are invasive ductal carcinomas of no special type (NST breast carcinomas). METHODS AND RESULTS: In this prospective, multicentric biomarker discovery study, we analyzed the expression of small non-coding RNAs (mainly microRNAs) in plasma by qPCR and evaluated their association with NST breast cancer. Large-scale expression profiling and subsequent validations have been performed in patient and control groups and compared with clinicopathological data. Small nuclear U6 snRNA, miR-548b-5p and miR-451a have been identified as candidate biomarkers. U6 snRNA was remarkably overexpressed in all the validations, miR-548b-5p levels were generally elevated and miR-451a expression was mostly downregulated in breast cancer groups. Combined U6 snRNA/miR-548b-5p signature demonstrated the best diagnostic performance based on the ROC curve analysis with AUC of 0.813, sensitivity 73.1% and specificity 82.6%. There was a trend towards increased expression of both miR-548b-5p and U6 snRNA in more advanced stages. Further, increased miR-548b-5p levels have been partially associated with higher grades, multifocality, Ki-67 positivity, and luminal B rather than luminal A samples. On the other hand, an association has been observed between high miR-451a expression and progesterone receptor positivity, lower grade, unifocal samples, Ki-67-negativity, luminal A rather than luminal B samples as well as improved progression-free survival and overall survival. CONCLUSIONS: Our results indicated that U6 snRNA and miR-548b-5p may have pro-oncogenic functions, while miR-451a may act as tumor suppressor in breast cancer.
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 12
- $a nádory prsu $x diagnóza $x genetika $x patologie $7 D001943
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $x genetika $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mikro RNA $x metabolismus $7 D035683
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a RNA malá jaderná $7 D012342
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jandáková, Eva $u Department of Pathology, Faculty of Medicine, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
- 700 1_
- $a Weinberger, Vít $u Department of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
- 700 1_
- $a Minář, Luboš $u Department of Obstetrics and Gynecology, Masaryk University and University Hospital Brno, Obilní trh 11, 602 00, Brno, Czech Republic
- 700 1_
- $a Hanzíková, Veronika $u Faculty Transfusion Center, General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
- 700 1_
- $a Dušková, Daniela $u Faculty Transfusion Center, General University Hospital in Prague, U Nemocnice 2, 128 08, Prague, Czech Republic
- 700 1_
- $a Faridová, Adéla $u Institute for Mother and Child Care, Podolské nábřeží 157/36, 147 00, Prague - Podolí, Czech Republic
- 700 1_
- $a Turyna, Radovan $u Institute for Mother and Child Care, Podolské nábřeží 157/36, 147 00, Prague - Podolí, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic
- 700 1_
- $a Hořínek, Aleš $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic $u 3rd Department of Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
- 700 1_
- $a Kohoutová, Milada $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague and General University Hospital in Prague, Albertov 4, 128 00, Prague, Czech Republic
- 773 0_
- $w MED00003392 $t Molecular biology reports $x 1573-4978 $g Roč. 49, č. 3 (2022), s. 1955-1971
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34993725 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135537 $b ABA008
- 999 __
- $a ok $b bmc $g 1822774 $s 1170556
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 49 $c 3 $d 1955-1971 $e 20220107 $i 1573-4978 $m Molecular biology reports $n Mol Biol Rep $x MED00003392
- GRA __
- $a Progres Q28/LF1 $p Charles University, Prague
- GRA __
- $a Progres Q25/LF1 $p Charles University, Prague
- GRA __
- $a RVO-VFN 64165 $p Ministry of Health of the Czech Republic
- GRA __
- $a CZ-DRO FNBr 65269705 $p Ministry of Health of the Czech Republic
- GRA __
- $a SSD2018\100022 $p Avast Foundation
- GRA __
- $a 1410002385 $p ČEPS, a.s.
- GRA __
- $a 1410002088 $p ČEPS, a.s.
- GRA __
- $a 1410002640 $p ČEPS, a.s.
- LZP __
- $a Pubmed-20220720